Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
US11117855B2 · kind B2 · utility
2Cited by
1References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2021 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | Feb 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.